Rockefeller Capital Management L.P. Dynavax Technologies Corp Transaction History

Rockefeller Capital Management L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	SELL	$10.27 - $13.29 $2,084 - $2,697	-203 Reduced 1.0%	20,060 $213,000
Q3 2022 Nov 02, 2022	BUY	$9.93 - $17.44 $114,850 - $201,711	11,566 Added 132.99%	20,263 $211,000
Q2 2022 Aug 12, 2022	BUY	$7.45 - $12.83 $1,467 - $2,527	197 Added 2.32%	8,697 $109,000
Q3 2021 Nov 12, 2021	BUY	$9.16 - $19.83 $77,860 - $168,555	8,500 New	8,500 $163,000
Q1 2021 May 11, 2021	SELL	$4.57 - $11.18 $648 - $1,587	-142 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$3.73 - $5.6 $529 - $795	142 New	142 $0
Q3 2020 Nov 13, 2020	SELL	$4.32 - $11.7 $17,280 - $46,800	-4,000 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$2.94 - $9.1 $11,760 - $36,400	4,000 New	4,000 $35,000

275

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.63B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.